drugset / Trial / NCT01495208
Open Label to Study to Evaluate Effect of Alfilbercept on Patients With (FVPED) Fibrovascular Pigment Epithelial Detachment
Phase 4
Withdrawn
Vitreous -Retina- Macula Consultants of New York
Regeneron Pharmaceuticals · collab
NaSingle-groupOpen-labelTreatment
Summary
This is an open label study to evaluate the efficacy of intravitreal aflibercept injection 2mg in patients with a persistent FVPED despite at least 6 consecutive injections with ranibizumab 0.5 mg.
Timeline
- Start
- 2011-12
- Primary completion
- 2012-10
- Completion
- 2012-10
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Aflibercept | Protein / enzyme biologic | 2 mg | Intravitreal |